Acceleron Pharma, Inc., A Wholly-owned Subsidiary Of Merck & Co., Inc., Rahway, Nj Usa
Clinical trials sponsored by Acceleron Pharma, Inc., A Wholly-owned Subsidiary Of Merck & Co., Inc., Rahway, Nj Usa, explained in plain language.
-
New drug shows promise for hard-to-treat lung-heart condition
Disease control CompletedThis study tested a drug called sotatercept in 164 adults with a specific type of pulmonary hypertension caused by heart failure. The goal was to see if it improves blood flow in the lungs and walking ability compared to a placebo. Participants received either the drug or a place…
Phase: PHASE2 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for advanced PAH: drug delays death and hospitalization
Disease control CompletedThis study tested a drug called sotatercept in 173 people with severe pulmonary arterial hypertension (PAH) who were at high risk of dying. Participants received either the drug or a placebo on top of their usual treatments. The goal was to see if the drug could delay death, the …
Phase: PHASE3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated May 11, 2026 20:41 UTC